ADC Therapeutics进行战略财务重组

2026-10-08 23:23

ADC Therapeutics (ADCT) said it is undergoing a strategic financial restructuring that includes an $86.6M private placement.
The restructuring is projected to extend the company's cash runway into 2029.
The $86.6M private investment in public equity (“PIPE”) financing is from existing investors Redmile, TCGX, and Nantahala Capital, and new investor Bain Capital Life Sciences.
The PIPE includes selling 12.9M common shares at $1.42 per share and pre-funded warrants to purchase 48.1 million common shares at $1.32.
The PIPE is expected to close on Oct. 22.
Also, a healthcare royalty agreement has been amended to remove a $150M change-of-control payment.
ADC Therapeutics will use the proceeds for funding of Zynlonta studies and bolster its balance sheet.

More on ADC Therapeutics